Patent · US Active

Plasma autoantibody biomarkers for basal like breast cancer

US12085569B2 · kind B2 · utility

0Cited by

11References

7Claims

0Family size

Assignees

ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · US
The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

Joshua LaBaer · Chandler, US
Jie Wang · Lake Bluff, US
Ji Qiu · Chandler, US
Garrick Wallstrom · Mesa, US
Karen Anderson · Guilford, US
Jin Park · Phoenix, US
Jonine Figueroa · Edinburgh, GB

Key dates

Filing date	Sep 8, 2022
Grant date	Sep 10, 2024
Priority date	—
Expiry date	Sep 8, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/158
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

Cancer patients make antibodies to tumor-derived proteins that are potential biomarkers for early detection. Twenty-eight antigens have been identified as potential biomarkers for the early detection of basal-like breast cancer (Tables 1, 2). Also, a 13-AAb classifier has been developed that differentiate patients with BLBC from healthy controls with 33% sensitivity at 98% specificity (Table 3).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.